DELPHI - EMERGING TECHNOLOGIES IN HEALTHCARE

Innovative digital strategies for the transformation of healthcare through the value chain, from R&D and clinical trials to optimized engagement through the patient journey

This virtual Panel brought together academic, consulting, and industry experts from the Biopharma and Medical Device sectors. They explored innovative digital strategies for the transformation of healthcare through the value chain, from R&D and clinical trials to optimized engagement through the patient journey.

The DELPHI cluster from Nantes Université in collaboration with Columbia University and Icahn School of Medicine at Mount Sinai had the chance to welcome live in Paris :

• Mr Martin Dubuc, MS, Group Senior Vice President, Head of Biogen Digital Health to discuss "Optimizing Patient Engagement with Digital Strategies"
• Mrs Nathalie Virag, PhD, Distinguished Scientist, Medtronic Corporate Technology and Innovation to discuss "Digital Innovation in Medical Devices"
• Mr Alex Devereson, PhD, Partner, McKinsey & Company, London and Mr Lieven Van der Veken, MD, Senior Partner, McKinsey & Company, London to discuss "Transforming Biopharma Innovation through Advanced Analytics"

The discussion included :

• Pr Françoise SIMON, PhD, Professor Emerita, Columbia University, Senior Faculty, Icahn School of Medicine at Mount Sinai
• Pr Frantz ROWE, PhD, expert in MedTech, Head of Master in Consulting, Research IEMN-IAE Board Member, and Editor of European Journal of Information Systems
• Pr Pierre-Antoine GOURRAUD, University Professor, Faculty of Medicine, Nantes University

Replay - EMERGING TECHNOLOGIES  IN HEALTHCARE

Chapter 1 - “Digital Innovation in Biopharma”

Martin Dubuc, MS, Group Senior Vice President, Head of Biogen Digital Health

Q1: What is Biogen specialized in ?
Q2 : Which technological progress are transforming medicine ?
Q3 : What are the use case at Biogen ?
Q4 : What are the 4 pillars of Biogen digital health ?
Ex 1 : MS Paths - Real world registry of high quality research data sets with over 20k patients
Ex 2 : MS LESION ANALYZER - Turn the data sets into valuable tools for research and clinical practice
Ex 3 : Radiomics : New combined use of data sets with machine learning to detect whta a human eye cannot see in an images
Ex 4 : Clinical trial predictive enrichment
Ex 5 : Digital biomarkers to measure and predict the evolution of disease
Q5: What difference are those tools making in the real world ?
Ex 6 : Intuition : Personalized healthcare - largest virtual observational study with over 21k patients enrolled
Ex 7 : MedRythms - Digital therapeutics
Conclusion : At Biogen, we value how we learn and fail and how we integrate the technologies to make a meaningfull difference

Chapter 2 - “Digital Innovation in Medical Devices”

Nathalie Virag, PhD, Distinguished Scientist, Medtronic Corporate Technology and Innovation

Q1 : What areas digital innovation is really helping ?
Q2 : How Modeling and Simulation can help to make a decision or predict an outcome ?
Q3 : Why is investing 2.5B$ in R&D going to help Medtronics lower the risk for patients with Modeling and Simulation ?
Ex 1: Trials @ Home - Reducing the size of clinical trials with Remote Decentralized Clinical Trial (RDCT)
Q4 : What form takes the digital techonology in clinical trials ?
Ex 2 : SaMD - Software as a medical device
Ex 3 : Digital Twin Vs Modeling in atrial fibrillation management
Ex 4 : Computational Modeling 
Conclusion : At Medtronics, we believe MedTech should act as a partner for co-investments in the Healthcare Ecosystem

Chapter 3 - “Transforming Biopharma Innovation through Advanced Analytics”

Alex Devereson, PhD, Partner, McKinsey & Company, London

Q1: What is one of the biggest challenge in transforming biopharma innovation through advanced analytics ?
Q2 : Why  AI in R&D is important ?
Q3 : What is the impact of AI in research when done right
Examples where RWE AA can have an impacts on R&D 
Q4 : What it takes to succeed 
Examples 

Chapter 4 - Global discussionFrantz Rowe, PhD, Professor of Information Systems, Nantes University
 

DELPHI aims to accelerate and facilitate the link between AI and Healthcare data application in Nantes. We support creative and disruptive student, researchers, industries and startups in a motivational, cheerful and high scientific and academic value statement.


Piloté par NExT à travers une aide de l’Etat gérée par l’ANR au titre du Programme d’Investissements d’Avenir (référence ANR-16-IDEX-0007), le dispositif bénéficie d’un soutien financier de Région Pays de la Loire et de Nantes Métropole.